Neoplasms
"Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Descriptor ID |
D009369
|
MeSH Number(s) |
C04
|
Concept/Terms |
Neoplasms- Neoplasms
- Neoplasia
- Neoplasias
- Neoplasm
- Tumors
- Tumor
Cancer- Cancer
- Cancers
- Malignant Neoplasms
- Malignant Neoplasm
- Neoplasm, Malignant
- Neoplasms, Malignant
- Malignancy
- Malignancies
Benign Neoplasms- Benign Neoplasms
- Neoplasms, Benign
- Benign Neoplasm
- Neoplasm, Benign
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms".
This graph shows the total number of publications written about "Neoplasms" by people in this website by year, and whether "Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 3 | 4 | 7 | 1996 | 6 | 5 | 11 | 1997 | 6 | 1 | 7 | 1998 | 10 | 3 | 13 | 1999 | 5 | 1 | 6 | 2000 | 7 | 4 | 11 | 2001 | 13 | 5 | 18 | 2002 | 14 | 6 | 20 | 2003 | 18 | 0 | 18 | 2004 | 16 | 7 | 23 | 2005 | 18 | 10 | 28 | 2006 | 37 | 14 | 51 | 2007 | 34 | 8 | 42 | 2008 | 54 | 14 | 68 | 2009 | 54 | 12 | 66 | 2010 | 40 | 10 | 50 | 2011 | 53 | 7 | 60 | 2012 | 44 | 8 | 52 | 2013 | 59 | 11 | 70 | 2014 | 80 | 11 | 91 | 2015 | 74 | 13 | 87 | 2016 | 81 | 14 | 95 | 2017 | 68 | 18 | 86 | 2018 | 81 | 14 | 95 | 2019 | 84 | 23 | 107 | 2020 | 107 | 14 | 121 | 2021 | 120 | 10 | 130 | 2022 | 135 | 1 | 136 | 2023 | 130 | 4 | 134 | 2024 | 77 | 33 | 110 | 2025 | 42 | 2 | 44 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasms" by people in Profiles.
-
Davies KD. Finding Rearrangements in the Cell-Free DNA Haystack. Clin Cancer Res. 2025 Jun 13; 31(12):2264-2266.
-
Jazowski SA, Achola EM, Nicholas LH, Kwon Y, Wood WA, Friese CR, Dusetzina SB. Medicare Plan Switching Among Beneficiaries With and Without a History of Cancer. JAMA Netw Open. 2025 Jun 02; 8(6):e2513394.
-
Schwatka NV, Dally M, Dye-Robinson A, Tenney L, Brown CE, Goering M, Williams B, S Newman L, J Bradley C. WeCanWork study: well-being of male cancer survivors working physically demanding jobs. BMC Public Health. 2025 May 31; 25(1):2025.
-
Clune S, Awolade P, Esquer H, Zhou Q, LaBarbera DV. CHD1L in cancer and beyond: structure, oncogenic functions, and therapeutic potential. J Exp Clin Cancer Res. 2025 May 30; 44(1):167.
-
Guo AA, Knapp MP, Evans JK, Faucheux AT, Price SN, Klepin HD, Levine B, Quattlebaum A, Bloomer C, Khoury L, Hunting JC, Elko CA, Olson E, Lycan TW. Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy. Future Oncol. 2025 Jun; 21(14):1787-1796.
-
Cooper JT, Svoboda E, Prochazka AV, Ha DM. Effects of cognitive-behavioral therapy for insomnia compared with controls among cancer survivors: a systematic review and meta-analysis of randomized trials. BMC Cancer. 2025 May 14; 25(1):871.
-
Fukuda R, Fujiwara Y, Maeda H, Pan C, Minayoshi Y, Yano H, Mizuta Y, Takano M, Yamada R, Saito Y, Hirata K, Imoto S, Yamasaki K, Oniki K, Saruwatari J, Otagiri M, Watanabe H, Komohara Y, Maruyama T. Lymph node macrophage-targeted interferon alpha boosts anticancer immune responses by regulating CD169-positive phenotype of macrophages. Mol Cancer. 2025 May 03; 24(1):132.
-
Galvin RT, Chen Y, Yuan Y, Cooney T, Howell R, Smith S, Arnold MA, Conces M, Leisenring W, Armstrong GT, Neglia JP, Turcotte LM. Temporal trends of subsequent central nervous system malignancies among survivors of childhood cancer. J Natl Cancer Inst. 2025 May 01; 117(5):1036-1045.
-
Green AL, Minard CG, Liu X, Safgren SL, Pinkney K, Harris L, Link G, DeSisto J, Voss S, Nelson MD, Reid JM, Fox E, Weigel BJ, Glade Bender J. Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. Clin Cancer Res. 2025 May 01; 31(9):1587-1595.
-
Dela Cruz FS, Fox E, DuBois SG, Friedman GK, Croop JM, Kim A, Morgenstern DA, Balis FM, Macy ME, Pressey JG, Watt T, Krystal JI, Vo KT, Mody R, Laetsch TW, Weigel BJ, O'Hara K, He CS, Aluri J, Okpara CE, Glade Bender JL. A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. Pediatr Blood Cancer. 2025 Jul; 72(7):e31692.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|